{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:44:41Z","timestamp":1793357081819,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["305608"],"award-info":[{"award-number":["305608"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["A-EvdL"],"award-info":[{"award-number":["A-EvdL"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["RP31\/2015"],"award-info":[{"award-number":["RP31\/2015"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203128\/Z\/16\/Z"],"award-info":[{"award-number":["203128\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006441","name":"Center for Outcomes Research and Evaluation, Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.kint.2019.07.014","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T11:23:52Z","timestamp":1565609032000},"page":"1292-1302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a\u00a0decade after its discovery"],"prefix":"10.1016","volume":"96","author":[{"given":"Anne-Els","family":"van de Logt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brenchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.07.014_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy--a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.07.014_bib2","first-page":"64","article-title":"Secondary membranous glomerulonephritis","volume":"7","author":"Glassock","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.07.014_bib5","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib7","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2215\/CJN.03850414","article-title":"M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy","volume":"9","author":"Hoxha","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib12","first-page":"109","article-title":"Anti-PLA(2)R antibodies in membranous nephropathy: ready for routine clinical practice?","volume":"70","author":"Hofstra","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7a-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/ki.2015.34","article-title":"Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up","volume":"87","author":"van de Logt","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/ki.2015.310","article-title":"Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy","volume":"88","author":"Ramachandran","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","article-title":"Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"421","author":"Dahnrich","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kint.2019.07.014_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ckj\/sfw121","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy","volume":"10","author":"Jullien","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2019.07.014_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biochi.2015.08.007","article-title":"Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy","volume":"118","author":"Seitz-Polski","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.kint.2019.07.014_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41581-018-0057-8","article-title":"HLA and kidney disease: from associations to mechanisms","volume":"14","author":"Robson","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(79)92118-4","article-title":"Strong association between idiopathic membranous nephropathy and HLA-DRW3","volume":"2","author":"Klouda","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.07.014_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-0039.1989.tb01741.x","article-title":"A\u00a0DQA1 allele is strongly associated with idiopathic membranous nephropathy","volume":"34","author":"Vaughan","year":"1989","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.kint.2019.07.014_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gfw001","article-title":"Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies","volume":"32","author":"Sekula","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib33","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy","volume":"24","author":"Lv","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ndt\/gfv399","article-title":"PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians","volume":"31","author":"Ramachandran","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib35","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib36","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2016060644","article-title":"HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy","volume":"28","author":"Le","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib37","doi-asserted-by":"crossref","first-page":"C398","DOI":"10.1152\/ajpcell.00239.2017","article-title":"Human soluble phospholipase A2 receptor is an inhibitor of the integrin-mediated cell migratory response to collagen-I","volume":"315","author":"Watanabe","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kint.2019.07.014_bib38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2019.07.014_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mehy.2009.07.033","article-title":"Air pollution as a potential contributor to the 'epidemic' of autoimmune disease","volume":"74","author":"Ritz","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.kint.2019.07.014_bib41","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib42","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ndt\/gfy022","article-title":"Primary glomerular nephropathy among hospitalized patients in a national database in China","volume":"33","author":"Li","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib43","article-title":"Smoking is a risk factor for the progression of idiopathic membranous nephropathy","volume":"9","author":"Yamaguchi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.07.014_bib44","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0085-2538(15)47011-5","article-title":"Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies","volume":"57","author":"Stengel","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib45","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ndt\/gfv080","article-title":"Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy","volume":"30","author":"Stehle","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1423-0127-17-81","article-title":"Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan","volume":"17","author":"Liu","year":"2010","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.kint.2019.07.014_bib47","doi-asserted-by":"crossref","first-page":"c253","DOI":"10.1159\/000320194","article-title":"Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy","volume":"117","author":"Kim","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2019.07.014_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.kint.2019.07.014_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/002215549904700704","article-title":"In\u00a0vivo antibody-mediated modulation of aminopeptidase A in mouse proximal tubular epithelial cells","volume":"47","author":"Mentzel","year":"1999","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.kint.2019.07.014_bib52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.174.1.464","article-title":"Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor","volume":"174","author":"Granata","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib53","doi-asserted-by":"crossref","first-page":"25862","DOI":"10.1074\/jbc.274.36.25862","article-title":"Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies","volume":"274","author":"Hellmark","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2019.07.014_bib54","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1074\/jbc.275.8.6030","article-title":"The Goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain","volume":"275","author":"Borza","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2019.07.014_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2007.05.001","article-title":"Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease","volume":"124","author":"Yang","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa0910500","article-title":"Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis","volume":"363","author":"Pedchenko","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib57","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1097\/01.ASN.0000096785.86791.68","article-title":"Tolerance and autoimmunity in anti-GBM disease","volume":"14","author":"Salama","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.kint.2019.07.014_bib59","article-title":"Plasma from patients with anti-glomerular basement membrane disease could recognize microbial peptides","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.07.014_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1681\/ASN.2014090877","article-title":"The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of pi","volume":"26","author":"Beck","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fimmu.2013.00235","article-title":"A\u00a0temporal model of human IgE and IgG antibody function","volume":"4","author":"Collins","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.autrev.2016.07.005","article-title":"Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease","volume":"15","author":"Qian","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2019.07.014_bib63","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.kint.2019.07.014_bib64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A\u00a0new classification system for IgG4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.humimm.2009.04.004","article-title":"The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity","volume":"70","author":"Zhao","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-14-19","article-title":"The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease","volume":"14","author":"Qu","year":"2013","journal-title":"BMC Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib67","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2013.08.032","article-title":"Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease","volume":"63","author":"Ohlsson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.07.014_bib68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cca.2018.12.027","article-title":"Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: clinical value assessment","volume":"490","author":"Cheng","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kint.2019.07.014_bib69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal\u00a0biopsies with membranous glomerulonephritis indicates subclass\u00a0switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2019.07.014_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158154","article-title":"Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy","volume":"11","author":"Hihara","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.07.014_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus\u00a0secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2019.07.014_bib72","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib73","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12026-016-8790-1","article-title":"IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study","volume":"64","author":"Yang","year":"2016","journal-title":"Immunol Res"},{"key":"10.1016\/j.kint.2019.07.014_bib74","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib75","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.07.014_bib76","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00467-009-1439-8","article-title":"IgG subclasses and complement pathway in segmental and global membranous nephropathy","volume":"25","author":"Segawa","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib77","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib78","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2019.07.014_bib79","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.07.014_bib80","doi-asserted-by":"crossref","first-page":"28869","DOI":"10.1074\/jbc.270.48.28869","article-title":"Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor","volume":"270","author":"Nicolas","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2019.07.014_bib81","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1038\/s41598-017-07028-8","article-title":"PLA2R binds to the annexin A2-S100A10 complex in human podocytes","volume":"7","author":"Fresquet","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2019.07.014_bib82","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.07.014_bib83","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A\u00a0heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib84","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes","volume":"30","author":"Herwig","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.07.014_bib85","first-page":"139","article-title":"KDIGO Clinical Practice Guidelines for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2019.07.014_bib86","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.07.014_bib87","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jca.21599","article-title":"Peptide GAM immunoadsorption therapy in primary membranous nephropathy\u00a0(PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy","volume":"33","author":"Hamilton","year":"2018","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.kint.2019.07.014_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92021","article-title":"Setting the target for pemphigus vulgaris therapy","volume":"2","author":"Ellebrecht","year":"2017","journal-title":"JCI Insight"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819308075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819308075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:54:24Z","timestamp":1777474464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819308075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0085253819308075"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.07.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736528198.793569178","asserted-by":"object"}]},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a\u00a0decade after its discovery","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}